Compare BCS & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCS | SNY |
|---|---|---|
| Founded | 1690 | 1994 |
| Country | United Kingdom | France |
| Employees | 98141 | 74846 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.0B | 104.5B |
| IPO Year | N/A | N/A |
| Metric | BCS | SNY |
|---|---|---|
| Price | $27.93 | $44.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $58.00 |
| AVG Volume (30 Days) | ★ 4.5M | 4.1M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | 1.94% | ★ 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.44 | $3.49 |
| Revenue Next Year | $4.27 | $6.10 |
| P/E Ratio | $10.92 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.68 | $40.89 |
| 52 Week High | $28.43 | $52.68 |
| Indicator | BCS | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 59.51 | 56.23 |
| Support Level | $25.45 | $42.30 |
| Resistance Level | $28.43 | $45.18 |
| Average True Range (ATR) | 0.48 | 0.72 |
| MACD | -0.03 | 0.22 |
| Stochastic Oscillator | 69.05 | 86.03 |
Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; Barclays UK (retail), UK corporate bank, private bank and wealth management, investment bank, and US consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The US consumer bank includes a co-branded credit card and unsecured lending business. The investment bank offers global markets, financing, and advisory services.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.